ETOPOSIDE TREATMENT IN RECURRENT MEDULLOBLASTOMA

Authors
BOOR R HUBER A GUTJAHR P
Citation
R. Boor et al., ETOPOSIDE TREATMENT IN RECURRENT MEDULLOBLASTOMA, Neuropediatrics, 25(1), 1994, pp. 39-41
Citations number
23
Categorie Soggetti
Pediatrics,Neurosciences
Journal title
Neuropediatrics → ACNP
ISSN journal
0174304X
Volume
25
Issue
1
Year of publication
1994
Pages
39 - 41
Database
ISI
SICI code
0174-304X(1994)25:1<39:ETIRM>2.0.ZU;2-B
Abstract
Five consecutive patients with recurrent medulloblastoma received etop oside 120 mg/m(2) for 5 to 7 days at 2 to 4-week intervals. Three pati ents with neuroaxis dissemination received additional intrathecal chem otherapy with methotrexate, cytosin arabinoside and prednisone. Toxici ty consisted of alopecia and mild neutropenia. Complete response was r egistered in two patients, partial response in one. Median survival wa s 19 months with the 3 responders living 6, 30 and 60 + months. Etopos ide seems to be an active agent in medulloblastoma.